Loading asset research
Dianthus Therapeutics Inc. Common Stock
DNTHNasdaq · USD · StocksQuote as of · Exchange session not verified$106.20
+2.83%
Today
DNTH
Loading 1D prices…
Market cap
$5.9B
Volume
732.8K
52w high
$117.8852w low
$32.22Company profile
Dianthus Therapeutics Inc. Common Stock
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
New York, NY, United States
Employees
92
Fiscal year end
1231
CIK
1690585
Session & valuation
Open$106.78
Previous close$103.28
Day high$109.79
Day low$105.00
30-day avg. volume657.5K
Outstanding shares55.9M
Diluted EPS-$4.20
Latest annual period
P/E (trailing)-25.29
P/E (forward)-23.03
Price / book4.97
Beta0.06
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares | $6B | $677.6M | +8.71% | $0.75 | -0.31% | Buy |
| AMRXAmneal Pharmaceuticals Inc. Class A Common Stock | $5.9B | $3B | +2.39% | $0.22 | +0.86% | Buy |
| LQDALiquidia Corporation Common Stock | $6B | $158.3M | -43.53% | -$0.80 | -1.68% | Buy |
| COGTCogent Biosciences Inc. Common Stock | $5.8B | $0.00 | — | -$2.16 | -1.97% | Buy |
| ORKAOruka Therapeutics Inc. Common Stock | $6.1B | $0.00 | — | -$1.85 | +0.78% | Buy |